Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 04:50 pm EST
Share
Lotus Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 5,389.37 million compared to TWD 3,057.78 million a year ago. Net income was TWD 2,079.38 million compared to TWD 348.28 million a year ago. Basic earnings per share from continuing operations was TWD 7.97 compared to TWD 1.34 a year ago. Diluted earnings per share from continuing operations was TWD 7.93 compared to TWD 1.33 a year ago.
For the nine months, sales was TWD 11,461.18 million compared to TWD 9,846.29 million a year ago. Net income was TWD 2,853.15 million compared to TWD 1,151.74 million a year ago. Basic earnings per share from continuing operations was TWD 10.96 compared to TWD 4.54 a year ago. Diluted earnings per share from continuing operations was TWD 10.91 compared to TWD 4.52 a year ago.
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.